Pre-order Enquiry
Download Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Inhaled nitric oxide is used for the treatment of several respiratory associated diseases.Such as chronic obstructive pulmonary disease (COPD), malaria treatment, tuberculosis treatment, acute respiratory distress syndrome (ARDS).Nitric oxide (nitrogen oxide or nitrogen monoxide) is a colorless gas with the formula NO. It is one of the principal oxides of nitrogen. Nitric oxide is a free radical, it has an unpaired electron, which is sometimes denoted by a dot in its chemical formula, ·NO. Nitric oxide is also a heteronuclear diatomic molecule.
The Inhaled Nitric Oxide market has witnessed a growth from USD XX million to USD XX million from 2017 to 2022. With a CAGR of X.X%, this market is estimated to reach USD XX million in 2029.
The report focuses on the Inhaled Nitric Oxide market size, segment size (mainly covering product type, application, and geography), competitor landscape, recent status, and development trends. Furthermore, the report provides strategies for companies to overcome threats posed by COVID-19.
Technological innovation and advancement will further optimize the performance of the product, enabling it to acquire a wider range of applications in the downstream market. Moreover, customer preference analysis, market dynamics (drivers, restraints, opportunities), new product release, impact of COVID-19, regional conflicts and carbon neutrality provide crucial information for us to take a deep dive into the Inhaled Nitric Oxide market.
Major Players in the Inhaled Nitric Oxide market are:
Praxair, Inc. (NOxBOX Ltd., Noxivent)
Beyond Air Inc.
Mallinckrodt Pharmaceuticals (INOMAX)
AIT Therapeutics, Inc.
Air Liquide (Kinox)
On the basis of types, the Inhaled Nitric Oxide market is primarily split into:
99.92% Purity
99.99% Purity
Others
On the basis of applications, the market covers:
ARDS
PPHN
Other Diseases
United States
Europe
China
Japan
India
Southeast Asia
Latin America
Middle East and Africa
Others
2021
The Inhaled Nitric Oxide market has witnessed a growth from USD XX million to USD XX million from 2017 to 2022. With a CAGR of X.X%, this market is estimated to reach USD XX million in 2029.
The report focuses on the Inhaled Nitric Oxide market size, segment size (mainly covering product type, application, and geography), competitor landscape, recent status, and development trends. Furthermore, the report provides strategies for companies to overcome threats posed by COVID-19.
Technological innovation and advancement will further optimize the performance of the product, enabling it to acquire a wider range of applications in the downstream market. Moreover, customer preference analysis, market dynamics (drivers, restraints, opportunities), new product release, impact of COVID-19, regional conflicts and carbon neutrality provide crucial information for us to take a deep dive into the Inhaled Nitric Oxide market.
Major Players in the Inhaled Nitric Oxide market are:
Praxair, Inc. (NOxBOX Ltd., Noxivent)
Beyond Air Inc.
Mallinckrodt Pharmaceuticals (INOMAX)
AIT Therapeutics, Inc.
Air Liquide (Kinox)
On the basis of types, the Inhaled Nitric Oxide market is primarily split into:
99.92% Purity
99.99% Purity
Others
On the basis of applications, the market covers:
ARDS
PPHN
Other Diseases
Major Region
s or countries covered in this report:United States
Europe
China
Japan
India
Southeast Asia
Latin America
Middle East and Africa
Others
Years considered for this report:
Historical Years:
2017-2021Base Year:
2021Estimated Year:
2022Forecast Period:
2022-2029Frequently Asked Questions
This market study covers the global and regional market with an
in-depth analysis of the
overall growth prospects...
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by
highlighting information on
different aspects including drivers, restraints...
